Shots:
- The global P-III (DESTINY-Breast05) trial data assessed Enhertu (trastuzumab DXd; 5.4mg/kg) vs trastuzumab emtansine in 1,635 HER2+ primary breast cancer pts with residual invasive disease in breast or axillary lymph nodes after neoadj. therapy & a high risk of recurrence
- Trial showed improved invasive disease-free survival (1EP), while OS (2EP) was immature during interim analysis & will be assessed in the future; data to be presented along with P-III (DESTINY-Breast11) trial results at ESMO’25, plus DESTINY-Breast05 data to be shared with global regulatory authorities
- Daiichi Sankyo discovered Enhertu, which is being jointly developed and commercialized by Daiichi Sankyo & AstraZeneca; based on various studies, Enhertu is approved in 85+ countries
Ref: Daiichi Sankyo | Image: AstraZeneca & Daiichi Sankyo | Press Release
Related News:- Daiichi Sankyo and AstraZeneca Receive the US FDA’s Priority Review for Enhertu + Perjeta to Treat HER2+ Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
